FIELD: medicine, pharmaceutics.
SUBSTANCE: this invention refers to new phenoxymethyl compounds of formula 
(I) or its pharmaceutically acceptable salts, wherein: HET represents a heterocyclic ring having formula A29 
or 
A31, wherein the far left part is connected to the group X of formula (I); X represents substituted phenyl or optionally substituted pyridinyl, wherein the substitutes are specified in C1-C4alkoxy and cyano; Z represents imidazo[1,2-a]pyridin-2-yl, imidazo[1,2-b]pyridazin-2-yl or imidazo[1,2-b]pyridazin-6-yl each of which can be substituted, wherein the substitutes are specified in C1-C4alkyl and a halogen atom; and each R2 are independently specified in C1-C4 alkyl inhibiting at least one phosphodiesterase 10, as well as to pharmaceutical compositions containing these compounds, and methods of treating various CNS disorders.
EFFECT: preparing the new compounds.
23 cl, 2 tbl, 732 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | 2009 |
|
RU2518089C2 |
| SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS AND THEIR USE FOR TREATMENT OF PATHOLOGICAL CONDITIONS | 2017 |
|
RU2773333C2 |
| NEW COMPOUNDS AND THEIR PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF INFLAMMATORY DISEASES | 2018 |
|
RU2785126C2 |
| GCN2 INHIBITORS AND THEIR USE | 2019 |
|
RU2811408C2 |
| HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | 2018 |
|
RU2797822C2 |
| BICYCLIC COMPOUND AND USE THEREOF FOR SUV39H2 INHIBITION | 2016 |
|
RU2729187C1 |
| MODULATORS OF NUCLEAR RECEPTORS | 2016 |
|
RU2715897C2 |
| HETEROARYL COMPOUNDS AS TKB INHIBITORS AND USE THEREOF | 2015 |
|
RU2742122C2 |
| ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF FOR INHIBITING NOREPINEPHRINE, DOPAMINE AND SEROTONIN REUPTAKE | 2005 |
|
RU2388751C2 |
| TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATING SKIN DISEASES | 2009 |
|
RU2544011C2 |
